German court deals blow to Sanofi over cholesterol drug
05-06-2019
Photobyphm / Shutterstock.com
A US judge yesterday, August 28 ruled in favour of Sanofi and Regeneron in the pharmaceutical companies’ long-running patent dispute with Amgen over the cholesterol drug Praluent.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Amgen, Sanofi, Regeneron, Praluent, Repatha, cholesterol, patent infringement, PCSK9
